Als donateur van onze stichting kunt u korting krijgen bij verschillende bedrijven. Ook voor prostasol en EGCG extracten bv.

30 april 2019: Oncotarget december 2018

Een reviewstudie gepubliceerd december 2018 in Oncotarget: Green tea extract for prevention of prostate cancer progression in patients on active surveillance bewijst dat een groene thee extract van grote waarde kan zijn voor prostaatkankerpatiënten die op een wait-and-see programma zitten. Lees het studierapport. (Abstract en referentielijst staat onderaan artikel

Ook een nieuwe kleinschalige studie bewijst dat een groene thee extract de PSA kan doen dalen bij prostaatkankerpatienten. Omdat de studie met slechts 44 patienten (22 vs 22) gerandomiseerd werd uitgevoerd was het verschil niet statistisch significant. Hoewel in de groene thee groep de PSA waarden op 6 maanden en 12 maanden bij de patienten beduidend lager waren dan in de placebogroep.

Lees het volledige studierapport: Effect of green tea catechins in patients with high-grade prostatic intraepithelial neoplasia: Results of a short-term double-blind placebo controlled phase II clinical trial in PDF formaat.

30 april 2019: lees ook dit artikel:

https://kanker-actueel.nl/groene-thee-en-in-het-bijzonder-egcg-in-relatie-tot-gezondheid-en-ziekte-waaronder-kanker-een-review-van-arts-bioloog-drs-engelbert-valstar-aan-de-hand-van-de-literatuur.html

Systematically evaluating the effectiveness and safety of novel agents such as green tea catechins, which have been well characterized in laboratory and early phase clinical trials, may inform the development of phase III clinical trials and ultimately provide strategies for chemoprevention in men on active surveillance for prostate cancer, for whom, currently, there are no options for reducing their risk.

. 2018 Dec 28; 9(102): 37798–37806.

Published online 2018 Dec 28. doi: 10.18632/oncotarget.26519

PMCID: PMC6340872

PMID: 30701033

Green tea extract for prevention of prostate cancer progression in patients on active surveillance

Nagi B. Kumar,¹ Shohreh I. Dickinson,² Michael J. Schell,³ Brandon J. Manley,⁴ Michael A. Poch,⁴ and Julio Pow-Sang⁴

Author information Article notes Copyright and License information Disclaimer

Abstract

Background

Active surveillance (AS) has evolved as a management strategy for men with low grade prostate cancer (PCa). However, these patients report anxiety, doubts about the possible progression of the disease as well as higher decisional conflict regarding selection of active surveillance, and have been reported to ultimately opt for treatment without any major change in tumor characteristics. Currently, there is a paucity of research that systematically examines alternate strategies for this target population.

Methods

We conducted a review the evidence from epidemiological, in vitro, preclinical and early phase trials that have evaluated green tea catechins (GTC) for secondary chemoprevention of prostate cancer, focused on men opting for active surveillanceof low grade PCa.

Results

Results of our review of the in vitro, preclinical and phase I-II trials, demonstrates that green tea catechins (GTC) can modulate several relevant intermediate biological intermediate endpoint biomarkers implicated in prostate carcinogenesis as well as clinical progression of PCa, without major side effects.

Discussion

Although clinical trials using GTC have been evaluated in early phase trials in men diagnosed with High-Grade Prostatic Intraepithelial Neoplasia, Atypical Small Acinar Proliferation and in men with localized disease before prostatectomy, the effect of GTC on biological and clinical biomarkers implicated in prostate cancer progression have not been evaluated in this patient population.

Conclusion

Results of these studies promise to provide a strategy for secondary chemoprevention, reduce morbidities due to overtreatment and improve quality of life in men diagnosed with low-grade PCa.

Footnotes

CONFLICTS OF INTEREST

None of the authors have any potential or competing interests.

FUNDING

This is supported by National Institute of Health Grant 5P30CA076292-20.

Go to:

REFERENCES

1. http://www.cancer.org/Cancer/ProstateCancer/DetailedGuide/prostate-cancer-key-statistics

2. Bruinsma SM, Bangma CH, Carroll PR, Leapman MS, Rannikko A, Petrides N, Weerakoon M, Bokhorst LP, Roobol MJ, Movember GAP3 consortium Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nat Rev Urol. 2016;13:151–67. doi: 10.1038/nrurol.2015.313. [PubMed] [CrossRef] [Google Scholar]

3. Ip S, Dahabreh IJ, Chung M, Yu WW, Balk EM, Iovin RC, Mathew P, Luongo T, Dvorak T, Lau J. An evidence review of active surveillance in men with localized prostate cancer. Evid Rep Technol Assess (Full Rep) 2011;204:1–341. [PMC free article] [PubMed] [Google Scholar]

4. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol. 2005;23:8165–9. doi: 10.1200/JCO.2005.03.3134. [PubMed] [CrossRef] [Google Scholar]

5. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106–31. doi: 10.1016/j.juro.2007.03.003. [PubMed] [CrossRef] [Google Scholar]

6. Hamdy FC, Donovan JL, Neal DE. 10-Year Outcomes in Localized Prostate Cancer. N Engl J Med. 2017;376:180. doi: 10.1056/NEJMc1614342. [PubMed] [CrossRef] [Google Scholar]

7. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126–31. doi: 10.1200/JCO.2009.24.2180. [PubMed] [CrossRef] [Google Scholar]

8. Klotz L. Active surveillance for low-risk prostate cancer. Curr Urol Rep. 2015;16:24. doi: 10.1007/s11934-015-0492-z. [PubMed] [CrossRef] [Google Scholar]

9. Maurice MJ, Abouassaly R, Kim SP, Zhu H. Contemporary Nationwide Patterns of Active Surveillance Use for Prostate Cancer. JAMA Intern Med. 2015;175:1569–71. doi: 10.1001/jamainternmed.2015.2835. [PubMed] [CrossRef] [Google Scholar]

10. Klotz L. Active surveillance and focal therapy for low-intermediate risk prostate cancer. Transl Androl Urol. 2015;4:342–54. doi: 10.3978/j.issn.2223-4683.2015.06.03. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

11. D'Amico AV. Personalizing the Use of Active Surveillance As an Initial Approach for Men With Newly Diagnosed Prostate Cancer. J Clin Oncol. 2015;33:3365–6. doi: 10.1200/JCO.2015.63.6118. [PubMed] [CrossRef] [Google Scholar]

12. Cooperberg MR, Carroll PR. Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. JAMA. 2015;314:80–2. doi: 10.1001/jama.2015.6036. [PubMed] [CrossRef] [Google Scholar]

13. Orom H, Underwood W, 3rd, Biddle C. Emotional Distress Increases the Likelihood of Undergoing Surgery among Men with Localized Prostate Cancer. J Urol. 2017;197:350–5. doi: 10.1016/j.juro.2016.08.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

14. Watts S, Leydon G, Eyles C, Moore CM, Richardson A, Birch B, Prescott P, Powell C, Lewith G. A quantitative analysis of the prevalence of clinical depression and anxiety in patients with prostate cancer undergoing active surveillance. BMJ Open. 2015;5:e006674. doi: 10.1136/bmjopen-2014-006674. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

15. Avery KN, Donovan JL, Horwood J, Neal DE, Hamdy FC, Parker C, Wade J, Lane A. The importance of dietary change for men diagnosed with and at risk of prostate cancer: a multi-centre interview study with men, their partners and health professionals. BMC Fam Pract. 2014;15:81. doi: 10.1186/1471-2296-15-81. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

16. Horwood JP, Avery KN, Metcalfe C, Donovan JL, Hamdy FC, Neal DE, Lane JA. Men's knowledge and attitudes towards dietary prevention of a prostate cancer diagnosis: a qualitative study. BMC Cancer. 2014;14:812. doi: 10.1186/1471-2407-14-812. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

17. Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovitch L, Malone WA, Crowell JA, Sigman CC. Chemoprevention of prostate cancer: concepts and strategies. Eur Urol. 1999;35:342–50. [PubMed] [Google Scholar]

18. Kumar N, Chornokur G. Molecular Targeted Therapies Using Botanicals for Prostate Cancer Chemoprevention. Transl Med (Sunnyvale) 2012;(Suppl 2):005. doi: 10.4172/2161-1025.S2-005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

19. Lieberman R. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials. Urology. 2001;57:224–9. [PubMed] [Google Scholar]

20. Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin A, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol. 2015;35:S276–S304. doi: 10.1016/j.semcancer.2015.09.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

21. Ito K. Prostate cancer in Asian men. Nat Rev Urol. 2014;11:197–212. doi: 10.1038/nrurol.2014.42. [PubMed] [CrossRef] [Google Scholar]

22. Jian L, Xie LP, Lee AH, Binns CW. Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer. 2004;108:130–5. doi: 10.1002/ijc.11550. [PubMed] [CrossRef] [Google Scholar]

23. Yuan JM. Cancer prevention by green tea: evidence from epidemiologic studies. Am J Clin Nutr. 2013;98:1676S–81S. doi: 10.3945/ajcn.113.058271. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

24. Connors SK, Chornokur G, Kumar NB. New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. Nutr Cancer. 2012;64:4–22. doi: 10.1080/01635581.2012.630158. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

25. Lee J, Demissie K, Lu SE, Rhoads GG. Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. Cancer Control. 2007;14:78–85. doi: 10.1177/107327480701400111. [PubMed] [CrossRef] [Google Scholar]

26. Adhami VM, Siddiqui IA, Sarfaraz S, Khwaja SI, Hafeez BB, Ahmad N, Mukhtar H. Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clin Cancer Res. 2009;15:1947–53. doi: 10.1158/1078-0432.CCR-08-2332. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

27. Kazi A, Daniel KG, Smith DM, Kumar NB, Dou QP. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol. 2003;66:965–76. [PubMed] [Google Scholar]

28. Kazi A, Wang Z, Kumar N, Falsetti SC, Chan TH, Dou QP. Structure-activity relationships of synthetic analogs of (-)-epigallocatechin-3-gallate as proteasome inhibitors. Anticancer Res. 2004;24:943–54. [PubMed] [Google Scholar]

29. Khan N, Mukhtar H. Modulation of signaling pathways in prostate cancer by green tea polyphenols. Biochem Pharmacol. 2013;85:667–72. doi: 10.1016/j.bcp.2012.09.027. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

30. Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem. 2001;276:13322–30. doi: 10.1074/jbc.M004209200. [PubMed] [CrossRef] [Google Scholar]

31. Smith DM, Wang Z, Kazi A, Li LH, Chan TH, Dou QP. Synthetic analogs of green tea polyphenols as proteasome inhibitors. Mol Med. 2002;8:382–92. [PMC free article] [PubMed] [Google Scholar]

32. Henning SM, Wang P, Said JW, Huang M, Grogan T, Elashoff D, Carpenter CL, Heber D, Aronson WJ. Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy. Prostate. 2015;75:550–9. doi: 10.1002/pros.22943. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

33. McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila) 2009;2:673–82. doi: 10.1158/1940-6207.CAPR-08-0167. [PubMed] [CrossRef] [Google Scholar]

34. Wang P, Aronson WJ, Huang M, Zhang Y, Lee RP, Heber D, Henning SM. Green tea polyphenols and metabolites in prostatectomy tissue: implications for cancer prevention. Cancer Prev Res (Phila) 2010;3:985–93. doi: 10.1158/1940-6207.CAPR-09-0210. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

35. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci U S A. 2001;98:10350–5. doi: 10.1073/pnas.171326098. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

36. Harper CE, Patel BB, Wang J, Eltoum IA, Lamartiniere CA. Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action. Prostate. 2007;67:1576–89. doi: 10.1002/pros.20643. [PubMed] [CrossRef] [Google Scholar]

37. Khan N, Adhami VM, Mukhtar H. Review: green tea polyphenols in chemoprevention of prostate cancer: preclinical and clinical studies. Nutr Cancer. 2009;61:836–41. doi: 10.1080/01635580903285056. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

38. Kim SJ, Amankwah E, Connors S, Park HY, Rincon M, Cornnell H, Chornokur G, Hashim AI, Choi J, Tsai YY, Engelman RW, Kumar N, Park JY. Safety and chemopreventive effect of Polyphenon E in preventing early and metastatic progression of prostate cancer in TRAMP mice. Cancer Prev Res (Phila) 2014;7:435–44. doi: 10.1158/1940-6207.CAPR-13-0427-T. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

39. Suttie A, Nyska A, Haseman JK, Moser GJ, Hackett TR, Goldsworthy TL. A grading scheme for the assessment of proliferative lesions of the mouse prostate in the TRAMP model. Toxicol Pathol. 2003;31:31–8. doi: 10.1080/01926230390173842. [PubMed] [CrossRef] [Google Scholar]

40. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 2006;66:1234–40. doi: 10.1158/0008-5472.CAN-05-1145. [PubMed] [CrossRef] [Google Scholar]

41. Brausi M, Rizzi F, Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol. 2008;54:472–3. doi: 10.1016/j.eururo.2008.03.100. [PubMed] [CrossRef] [Google Scholar]

42. Chow HH, Cai Y, Alberts DS, Hakim I, Dorr R, Shahi F, Crowell JA, Yang CS, Hara Y. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev. 2001;10:53–8. [PubMed] [Google Scholar]

43. Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA, Dorr RT, Hara Y, Alberts DS. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res. 2003;9:3312–9. [PubMed] [Google Scholar]

44. Chow HH, Hakim IA, Vining DR, Crowell JA, Cordova CA, Chew WM, Xu MJ, Hsu CH, Ranger-Moore J, Alberts DS. Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev. 2006;15:2473–6. doi: 10.1158/1055-9965.EPI-06-0365. [PubMed] [CrossRef] [Google Scholar]

45. Chow HH, Hakim IA, Vining DR, Crowell JA, Ranger-Moore J, Chew WM, Celaya CA, Rodney SR, Hara Y, Alberts DS. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res. 2005;11:4627–33. doi: 10.1158/1078-0432.CCR-04-2549. [PubMed] [CrossRef] [Google Scholar]

46. Chow HH, Hakim IA, Vining DR, Crowell JA, Tome ME, Ranger-Moore J, Cordova CA, Mikhael DM, Briehl MM, Alberts DS. Modulation of human glutathione s-transferases by polyphenon e intervention. Cancer Epidemiol Biomarkers Prev. 2007;16:1662–6. doi: 10.1158/1055-9965.EPI-06-0830. [PubMed] [CrossRef] [Google Scholar]

47. Isbrucker RA, Edwards JA, Wolz E, Davidovich A, Bausch J. Safety studies on epigallocatechin gallate (EGCG) preparations. Part 2: dermal, acute and short-term toxicity studies. Food Chem Toxicol. 2006;44:636–50. doi: 10.1016/j.fct.2005.11.003. [PubMed] [CrossRef] [Google Scholar]

48. Kumar NB, Pow-Sang J, Egan KM, Spiess PE, Dickinson S, Salup R, Helal M, McLarty J, Williams CR, Schreiber F, Parnes HL, Sebti S, Kazi A, et al. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. Cancer Prev Res (Phila) 2015;8:879–87. doi: 10.1158/1940-6207.CAPR-14-0324. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

49. Pisters KM, Newman RA, Coldman B, Shin DM, Khuri FR, Hong WK, Glisson BS, Lee JS. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol. 2001;19:1830–8. doi: 10.1200/JCO.2001.19.6.1830. [PubMed] [CrossRef] [Google Scholar]

50. Ullmann U, Haller J, Decourt JD, Girault J, Spitzer V, Weber P. Plasma-kinetic characteristics of purified and isolated green tea catechin epigallocatechin gallate (EGCG) after 10 days repeated dosing in healthy volunteers. Int J Vitam Nutr Res. 2004;74:269–78. doi: 10.1024/0300-9831.74.4.269. [PubMed] [CrossRef] [Google Scholar]

51. Ullmann U, Haller J, Decourt JP, Girault N, Girault J, Richard-Caudron AS, Pineau B, Weber P. A single ascending dose study of epigallocatechin gallate in healthy volunteers. J Int Med Res. 2003;31:88–101. doi: 10.1177/147323000303100205. [PubMed] [CrossRef] [Google Scholar]

52. Kapetanovic IM, Crowell JA, Krishnaraj R, Zakharov A, Lindeblad M, Lyubimov A. Exposure and toxicity of green tea polyphenols in fasted and non-fasted dogs. Toxicology. 2009;260:28–36. doi: 10.1016/j.tox.2009.03.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

53. Schmidt M, Schmitz HJ, Baumgart A, Guedon D, Netsch MI, Kreuter MH, Schmidlin CB, Schrenk D. Toxicity of green tea extracts and their constituents in rat hepatocytes in primary culture. Food Chem Toxicol. 2005;43:307–14. doi: 10.1016/j.fct.2004.11.001. [PubMed] [CrossRef] [Google Scholar]

54. Wu KM, Yao J, Boring D. Green tea extract-induced lethal toxicity in fasted but not in nonfasted dogs. Int J Toxicol. 2011;30:19–20. doi: 10.1177/1091581810387445. [PubMed] [CrossRef] [Google Scholar]

55. Nguyen MM, Ahmann FR, Nagle RB, Hsu CH, Tangrea JA, Parnes HL, Sokoloff MH, Gretzer MB, Chow HH. Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities. Cancer Prev Res (Phila) 2012;5:290–8. doi: 10.1158/1940-6207.CAPR-11-0306. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

56. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev. 1997;29:413–580. [PubMed] [Google Scholar]

57. Donovan JL, Chavin KD, Devane CL, Taylor RM, Wang JS, Ruan Y, Markowitz JS. Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. Drug Metab Dispos. 2004;32:906–8. doi: 10.1124/dmd.104.000083. [PubMed] [CrossRef] [Google Scholar]

58. Tosoian JJ, Carter HB, Lepor A, Loeb S. Active surveillance for prostate cancer: current evidence and contemporary state of practice. Nat Rev Urol. 2016;13:205–15. doi: 10.1038/nrurol.2016.45. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

59. Adamy A, Yee DS, Matsushita K, Maschino A, Cronin A, Vickers A, Guillonneau B, Scardino PT, Eastham JA. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol. 2011;185:477–82. doi: 10.1016/j.juro.2010.09.095. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

60. Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int. 2008;101:165–9. doi: 10.1111/j.1464-410X.2007.07190.x. [PubMed] [CrossRef] [Google Scholar]

61. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, Walsh PC. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol. 2010;28:2810–6. doi: 10.1200/JCO.2009.25.7311. [PubMed] [CrossRef] [Google Scholar]

62. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll PR. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol. 2011;185:1656–60. doi: 10.1016/j.juro.2010.12.042. [PubMed] [CrossRef] [Google Scholar]

63. Klotz L. Defining ‘progression’ and triggers for curative intervention during active surveillance. Curr Opin Urol. 2015;25:258–66. [PubMed] [Google Scholar]

64. Patel HD, Feng Z, Landis P, Trock BJ, Epstein JI, Carter HB. Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer. J Urol. 2014;191:629–37. doi: 10.1016/j.juro.2013.09.029. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

65. Iremashvili V, Manoharan M, Lokeshwar SD, Rosenberg DL, Pan D, Soloway MS. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients. BJU Int. 2013;111:396–403. doi: 10.1111/j.1464-410X.2012.11295.x. [PubMed] [CrossRef] [Google Scholar]

66. San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol. 2011;185:471–6. doi: 10.1016/j.juro.2010.09.115. [PubMed] [CrossRef] [Google Scholar]

67. Tosoian JJ, Loeb S, Epstein JI, Turkbey B, Choyke PL, Schaeffer EM. Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. Am Soc Clin Oncol Educ Book. 2016;35:e235–45. doi: 10.14694/EDBK_159244. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

68. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011;185:1650–5. doi: 10.1016/j.juro.2010.12.032. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

69. Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, et al. The prostate health index selectively identifies clinically significant prostate cancer. J Urol. 2015;193:1163–9. doi: 10.1016/j.juro.2014.10.121. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

70. Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB, Trock B, Sokoll LJ. Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol. 2012;188:1131–6. doi: 10.1016/j.juro.2012.06.009. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

71. Hirama H, Sugimoto M, Ito K, Shiraishi T, Kakehi Y. The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort. J Cancer Res Clin Oncol. 2014;140:257–63. doi: 10.1007/s00432-013-1566-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

72. Kumar NB, Pow-Sang J, Spiess PE, Park J, Salup R, Williams CR, Parnes H, Schell MJ. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. Oncotarget. 2016;7:70794–802. doi: 10.18632/oncotarget.12222. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

73. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192–202. doi: 10.1056/NEJMoa0908127. [PubMed] [CrossRef] [Google Scholar]

74. Hamilton RJ, Kahwati LC, Kinsinger LS. Knowledge and use of finasteride for the prevention of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:2164–71. doi: 10.1158/1055-9965.EPI-10-0082. [PubMed] [CrossRef] [Google Scholar]

75. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, 3rd, Crawford ED, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) JAMA. 2009;301:39–51. doi: 10.1001/jama.2008.864. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

76. Parsons JK, Pierce JP, Mohler J, Paskett E, Jung SH, Humphrey P, Taylor JR, Newman VA, Barbier L, Rock CL, Marshall J. A randomized trial of diet in men with early stage prostate cancer on active surveillance: rationale and design of the Men's Eating and Living (MEAL) Study (CALGB 70807 ) Contemp Clin Trials. 2014;38:198–203. doi: 10.1016/j.cct.2014.05.002. [PMC free article] [PubMed] [CrossRef] [Google Scholar]